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were collected for the health care services. Out-of-pocket (OOP) costs were the portion 
of individuals’ total payments for the health care services. To estimate the health care 
and OOP costs, a multivariable linear regression analysis was performed. Costs were 
adjusted for patient demographics and comorbidities. All costs were inﬂated using the 
medical component of the 2008 Consumer Price Index (CPI). RESULTS: There were 
873 individuals with PsO (mean age = 51 years; 52% female), and 160,617 individuals 
without PsO, (mean age = 48 years; 58% female). Annual per capita health care costs 
for individuals with PsO were higher than those for individuals without PsO ($4543 
vs. $3828; P = 0.0007). Annual per capita OOP costs for individuals with PsO were 
also higher than those of individuals without PsO ($1250 vs. $917; P < 0.0001). The 
total annual per capita direct medical costs was $5793 when combining health care 
and OOP costs for PsO. The US national annual estimates of health care, OOP, and 
total direct medical costs for PsO were $0.77 billion, $0.36 billion, and $1.1 billion, 
respectively. CONCLUSIONS: The direct medical costs associated with PsO are 
substantial not only to health care payers but to patients as well. The extent to which 
appropriate and early diagnosis and treatment of PsO reduce total health care costs 
for individuals with these diseases should be examined.
PSY11
THE INDIRECT COSTS OF INFLAMMATORY BOWEL DISEASE: 
EVIDENCE FROM UNITED STATES NATIONAL SURVEY DATA
Loﬂand J1, Naim A1, Rizzo J2, Gunnarsson C3, Chen J4, Waters H1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Stony Brook University, Stony 
Brook, NY, USA, 3S2 Statistical Solutions Inc, Cincinnati, OH, USA, 4College of Staten Island/
CUNY, Staten Island, NY, USA
OBJECTIVES: To quantify individual and national estimates of the indirect costs of 
inﬂammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), 
using national survey data. METHODS: This was a retrospective study using 1996–
2006 data from the Medical Expenditure Panel Survey (MEPS). Individuals self-
reported health conditions were mapped to the International Classiﬁcation of Diseases, 
9th Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic codes. Individuals with an 
ICD-9-CM diagnostic code of 555.x (CD) or 556.x (UC) were categorized as having 
IBD. A two-part model was speciﬁed to estimate the probability of time lost from 
work and the annual number of workdays missed due to illness, conditional on missing 
at least 1 workday. The annual missed workdays were combined with MEPS earnings 
information to estimate individual and national indirect costs. RESULTS: There were 
200 patients with IBD (mean age = 43.0 years; 54% Female), and 89,846 individuals 
without IBD (mean age = 40.8; 52% Female), included in the analysis. The study 
revealed 71.9% (144/200) of individuals with IBD missed work as compared with 
58.3% (52,110/89,846) of those without IBD (p = 0.0001). Among those individuals 
who missed work, individuals with IBD had a mean annual number of missed work-
days of 13.95 versus 9.83 missed workdays for individuals without IBD (p = 0.004). 
The per capita indirect costs associated with the incremental difference in annual lost 
workdays between those with and without IBD was $485. The estimated national 
indirect costs associated with IBD were $205 million per year. CONCLUSIONS: 
Compared to individuals without IBD, individuals with IBD have a higher probability 
of missing work and missing more workdays. The per capita and national annual 
indirect costs associated with IBD are substantial. The ability of appropriate and early 
diagnosis and treatment of IBD to reduce time lost from work and indirect costs for 
individuals with IBD should be examined.
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OBJECTIVES: To compare direct and absenteeism-related indirect expenditures 
among employees suffering from an AIID pre and post anti-TNF use. METHODS: A 
retrospective analysis was performed using the Thomson Reuters MarketScan® and 
the Health and Productivity Management databases (2000–2007). Study group con-
sisted of members with primary diagnosis for at least one of six AIIDs (Rheumatoid 
Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing 
Spondylosis) and at least one prescription for an anti-TNF (adalimumab, etanercept, 
or inﬂiximab) in the same calendar year. Direct expenditures included medical expen-
ditures (inpatient, outpatient, emergency department, and other medical services) and 
pharmacy expenditures. Indirect expenditures included expenditures related to absen-
teeism. Regression analysis was used to compare the mean number of annual absentee 
days, indirect expenditures associated with absences, direct expenditures (medical and 
pharmacy), and total expenditures during the 12 months prior versus the 12 months 
following initiation of anti-TNF treatment. RESULTS: The study group (n = 689) was 
39% female with 94% in a managed care plan and had a mean age of 44.3 years. 
Only 22% had more than one AIID condition. Following the use of anti-TNFs, 
absenteeism decreased by 15.4% with lower indirect expenditures ($1172 vs. $1000), 
lower medical expenditures ($7517 vs. $6434), and lower non anti-TNF pharmacy 
expenditures ($1934 vs. $1604). Direct expenditures were higher ($22,658 vs. $9450) 
due to the cost of anti-TNF treatment ($14,620). Consequently, total expenditures 
(direct and indirect) were also higher following anti-TNF use ($23,657 vs. $10,623). 
CONCLUSIONS: AIIDs are debilitating disorders that result in reduced productivity 
and time lost from work. Members with at least one AIID who received anti-TNF 
treatments, had lower absenteeism and indirect health care costs and higher direct 
costs. Appropriate management of these conditions with anti-TNF agents may provide 
greater indirect costs savings which could offset the direct costs.
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OBJECTIVES: To compare direct and absenteeism-related indirect expenditures 
among employees with inﬂammatory bowel disease (IBD) (Crohn’s Disease, Ulcerative 
Colitis) with employees who do not have IBD. METHODS: A retrospective analysis 
was performed using the Thomson Reuters MarketScan® and the Health and Produc-
tivity Management databases between 2000–2006. Propensity analysis adjusting for 
various demographic and clinical variables was used to create 1) control: no diagnosis 
of any IBD; and 2) IBD group: primary diagnosis of at least one IBD. Direct expen-
ditures included medical expenditures (inpatient, outpatient, emergency department, 
and other medical services) and pharmacy expenditures. Indirect expenditures 
included expenditures related to absenteeism. Regression analysis was used to compare 
the mean number of annual absentee days, indirect expenditures associated with 
absences, direct expenditures (medical and pharmacy), and total expenditures between 
the two groups. RESULTS: The 2201 employees in the IBD group were matched to 
8,788 employees in the control group (mean age 42.2 years; mean risk score was 3.43; 
40% female; with 94% in managed care). Compared to the control group, the IBD 
group had slightly higher rate of absenteeism (9.1 vs. 9.0 days, slightly higher indirect 
expenditures ($1170 vs. $1129), higher direct expenditures ($8870 vs. $7500) includ-
ing medical expenditures ($6860 vs. $6096), and non anti-TNF pharmacy expendi-
tures ($1609 vs. $1404). The total expenditures (direct and indirect) were also higher 
for the IBD group ($9950 vs. $8630) compared to the control group. CONCLU-
SIONS: IBD is a debilitating disease that results in reduced productivity and time lost 
from work. Employees with IBD have a higher total health care expenditure burden. 
Appropriate management of IBD can reduce costs for employers and payers. Further 
analyses are needed to determine the impact of various treatment(s) on lost productiv-
ity and direct and indirect expenditures.
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OBJECTIVES: To compare direct and absenteeism-related indirect expenditures pre- 
and post anti-TNF use among employees with inﬂammatory bowel disease (IBD). 
METHODS: A retrospective analysis was performed using the Thomson Reuters 
MarketScan® and the Health and Productivity Management databases between 
2000–2007. The study group consisted of individuals who had a primary diagnosis 
of at least one IBD and had at least one prescription for an anti-TNF agent (adalim-
umab, etanercept, or inﬂiximab) in the same calendar year. Direct expenditures 
included medical expenditures (inpatient, outpatient, emergency department, and 
other medical services) and pharmacy expenditures. Indirect expenditures included 
expenditures related to absenteeism. Regression analysis was used to compare the 
mean number of annual absence days and associated indirect expenditures, direct 
expenditures (medical and pharmacy), and total expenditures during the 12 months 
prior versus the 12 months following initiation of anti-TNF treatment. RESULTS: 
The study group had 87 members with a mean age of 41 years, 31% female, and 92% 
in a managed care plan. Following the use of anti-TNF agents, absenteeism was 39.8% 
lower (9.8 days vs.5.9 PMPY), and a similar decrease in indirect expenditures associ-
ated with absenteeism ($1,172 vs. $1,000) was observed. However, direct expendi-
tures were higher ($35,662 vs. $16,399) following the use of anti-TNF agents. This 
increase was primarily due to the cost of the anti-TNF agents themselves ($17,389), 
though annual medical expenditures were 13.2% higher ($15,810 vs. $13,968). Con-
sequently, total expenditures (direct and indirect) were also higher following anti-TNF 
use ($36,392 vs. $17,596). CONCLUSIONS: IBD results in reduced productivity and 
time lost from work. Members with at least one IBD who received anti-TNFs had 
lower absenteeism and lower indirect costs and higher direct costs. Employers and 
payers can develop appropriate management strategies like anti-TNF therapy to 
improve productivity and reduce indirect costs which may further offset total health 
care costs.
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OBJECTIVES: Develop a cost study and frequency of care for patients with chronic 
pain or neuropathic pain by occupational disease or consequences of occupational 
accidents in Colombia between 2002 and 2008, from the perspective of third-party 
